The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Outcomes and options for R/R AML patients who fail venetoclax-based salvage therapy
Andrius Zucenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses outcomes for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) who fail venetoclax-based salvage therapies, commenting on poor prognosis. Dr Zucenka reports that venetoclax re-initiation or low-dose cytarabine plus glasdegib may be possible options for patients in this subgroup. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
